First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

(2010) M. J. van den Bent et al.   CLINICAL CANCER RESEARCH

Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs and p53

(2009) S C Naumann et al.   BRITISH JOURNAL OF CANCER

MGMTPromoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951

(2009) Mathilde C.M. Kouwenhoven et al.   NEURO-ONCOLOGY

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

(2009) H. J. Dubbink et al.   NEUROLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric Gliomas

(2008) Justin S. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY